Kala Pharmaceuticals Stock Jumps as FDA Accepts Drug Application For Eye Condition

 Shares of Kala Pharmaceuticals Inc. on Tuesday jumped about 79% in after-hours trading after the company said the U.S. Food and Drug Administration accepted its investigational new drug application for the treatment of an eye rare condition through its KPI-012 product candidate.

Shares were trading about 79% higher at $7.01. For the year, shares are down about 94%.

The pharmaceutical company said KPI-012 is aimed at treating persistent corneal epithelial defects, which can result after a corneal injury.

"We are working closely with investigators to initiate our Phase 2b clinical trial of KPI-012 for PCED in the first quarter of 2023," Chief Medical Officer Kim Brazzell said.

https://www.marketscreener.com/quote/stock/KALA-PHARMACEUTICALS-INC-36926679/news/Kala-Pharmaceuticals-Stock-Jumps-79-as-FDA-Accepts-Drug-Application-For-Eye-Condition-42623581/